Provided by Tiger Trade Technology Pte. Ltd.

XILIO THERAPEUTICS, INC.

0.5409
+0.02104.04%
Post-market: 0.56410.0232+4.29%18:49 EST
Volume:454.37K
Turnover:239.75K
Market Cap:36.53M
PE:-0.89
High:0.5483
Open:0.5200
Low:0.5100
Close:0.5199
52wk High:1.70
52wk Low:0.5095
Shares:67.54M
Float Shares:36.44M
Volume Ratio:0.77
T/O Rate:1.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6100
EPS(LYR):-1.0884
ROE:-908.28%
ROA:-26.26%
PB:-4.51
PE(LYR):-0.50

Loading ...

Company Profile

Company Name:
XILIO THERAPEUTICS, INC.
Exchange:
NASDAQ
Establishment Date:
2016
Employees:
64
Office Location:
828 Winter Street,Suite 300,Waltham,Massachusetts,United States
Zip Code:
02451
Fax:
- -
Introduction:
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

Directors

Name
Position
Rene Russo
President, Chief Executive Officer and Director
Sara M. Bonstein
Chair of the Board
Akintunde Bello
Director
Aoife Brennan
Director
Christina Rossi
Director
Daniel Curran
Director
James Shannon
Director
Robert Ross
Director
Yuan Xu
Director

Shareholders

Name
Position
Rene Russo
President, Chief Executive Officer and Director
Kevin Brennan
Senior Vice President, Finance and Accounting
Christopher Frankenfield
Chief Financial and Operating Officer
Katarina Luptakova
Chief Medical Officer